{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:31:00Z","timestamp":1789047060829,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T00:00:00Z","timestamp":1525046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Five\u2010year overall survival for high\u2010risk Follicular Lymphoma International Prognostic Index follicular lymphoma is only approximately 50% compared with 90% for low risk. To evaluate an approach to improve upon this poor outcome, we completed an exploratory phase II trial of intensified treatment for patients with intermediate and high\u2010risk follicular lymphoma. Front\u2010line treatment with chemo\u2010immunotherapy consisting of rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone was followed by radio\u2010 immunotherapy with 90\u2010Yttrium ibritumomab tiuxetan consolidation, and 2\u00a0years of rituximab maintenance. The 5\u2010year overall survival for intermediate and high\u2010risk patients was 88% and 83%, respectively. Of 33 enrolled patients, 3 were off study before receiving radio\u2010immunotherapy. Three months post radio\u2010immunotherapy, 28\/33 (85%) patients had achieved complete response including 6 patients who had only a partial response to chemo\u2010immunotherapy and converted to complete response after radio\u2010immunotherapy. The 5\u2010year progression\u2010free survival for intermediate and high risk was 79% and 58%, respectively. Nine of 19 patients with molecular markers patients remain in molecular and clinical complete remission with a median follow\u2010up of 48\u00a0months (range 3\u201084\u00a0months). Post radio\u2010immunotherapy, hematologic toxicities were mostly grade 1 and 2. However, asymptomatic grade 3 or 4 thrombocytopenia and neutropenia occurred in 11%\u201036% and 10%\u201024% of patients, respectively. Myelodysplastic syndrome occurred in 1 patient 4\u00a0years post treatment. Whereas many patients had prolonged B\u2010cell reduction and low immunoglobulin levels post treatment, previous immunities to rubella were maintained. More aggressive upfront approaches such as this may benefit higher risk follicular lymphoma, but confirmatory trials are required. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>: NCT01446562.<\/jats:p>","DOI":"10.1002\/hon.2513","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T16:16:00Z","timestamp":1525104960000},"page":"525-532","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of newly diagnosed high\u2010risk and intermediate\u2010risk follicular lymphoma with <sup>90<\/sup>Y ibritumomab tiuxetan in a phase II study"],"prefix":"10.1002","volume":"36","author":[{"given":"Neil L.","family":"Berinstein","sequence":"first","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre  Toronto ON Canada"},{"name":"Department of Medicine University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-3506","authenticated-orcid":false,"given":"Nancy M.","family":"Pennell","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Sunnybrook Health Sciences Centre  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Weerasinghe","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Buckstein","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre  Toronto ON Canada"},{"name":"Department of Medicine University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Piliotis","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre  Toronto ON Canada"},{"name":"Department of Medicine University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Imrie","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre  Toronto ON Canada"},{"name":"Department of Medicine University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Chodirker","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre  Toronto ON Canada"},{"name":"Department of Medicine University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary\u2010Anne","family":"Cussen","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Miles","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marciano D.","family":"Reis","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Sunnybrook Health Sciences Centre  Toronto ON Canada"},{"name":"Department of Medicine University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina","family":"Ghorab","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Sunnybrook Health Sciences Centre  Toronto ON Canada"},{"name":"Department of Medicine University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre Sunnybrook Health Sciences Centre  Toronto ON Canada"},{"name":"Department of Medicine University of Toronto  Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp053"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.07.008"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi819"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2010.07.008"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2006.050050"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0407"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507319"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1553"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"issue":"22","key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood.V128.22.1793.1793","article-title":"Short course of Bendamustine and rituximab followed by 90Y\u2010Ibritumomab Tiuxetan in patients with chemotherapy\u2010naive follicular lymphoma (FOL\u2010BRITe): final report of response rates and progression free survival","volume":"128","author":"Costa CA","year":"2016","journal-title":"Blood"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5083"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2882"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12120"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694356"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12220"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:43:42Z","timestamp":1695012222000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,30]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1002\/hon.2513"],"URL":"https:\/\/doi.org\/10.1002\/hon.2513","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,30]]},"assertion":[{"value":"2018-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}